Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note published on Monday, Marketbeat reports. The brokerage issued a buy rating and a $65.00 target price on the stock. HC Wainwright also issued estimates for Jasper Therapeutics’ Q1 2024 earnings at ($1.43) EPS, Q2 2024 earnings at ($1.36) EPS, Q3 2024 earnings at ($1.41) EPS, Q4 2024 earnings at ($1.56) EPS, FY2024 earnings at ($5.75) EPS, FY2025 earnings at ($5.19) EPS, FY2026 earnings at ($5.42) EPS, FY2027 earnings at ($6.28) EPS and FY2028 earnings at ($6.25) EPS.

Several other equities analysts also recently weighed in on the company. Royal Bank of Canada started coverage on Jasper Therapeutics in a research report on Thursday, March 28th. They set an outperform rating and a $70.00 target price on the stock. Oppenheimer reaffirmed an outperform rating and set a $80.00 price target on shares of Jasper Therapeutics in a research note on Thursday, March 7th. TD Cowen began coverage on shares of Jasper Therapeutics in a research note on Monday, March 18th. They set an outperform rating for the company. Finally, Evercore ISI assumed coverage on Jasper Therapeutics in a research report on Wednesday, April 3rd. They set an outperform rating and a $65.00 price target for the company. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and an average target price of $64.29.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $21.19 on Monday. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01. The stock has a fifty day moving average of $25.52 and a two-hundred day moving average of $15.08. The company has a market capitalization of $319.12 million, a price-to-earnings ratio of -3.42 and a beta of 2.25.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.15. On average, analysts forecast that Jasper Therapeutics will post -5 EPS for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in shares of Jasper Therapeutics in the 1st quarter worth approximately $2,343,000. Concurrent Investment Advisors LLC acquired a new position in Jasper Therapeutics in the first quarter worth $599,000. Kingdon Capital Management L.L.C. raised its holdings in shares of Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock worth $2,793,000 after purchasing an additional 500,000 shares during the period. Opaleye Management Inc. bought a new position in shares of Jasper Therapeutics in the 4th quarter worth about $3,144,000. Finally, Ieq Capital LLC acquired a new position in shares of Jasper Therapeutics in the 4th quarter valued at about $43,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.